Research Grade Ruplizumab ( 卢利珠单抗 )
- 发布日期： 2020-10-13
- 更新日期： 2026-02-05
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00002
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
220651-94-5
|
| 保质期 |
一年
|
| 抗体名 |
Ruplizumab ( 卢利珠单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
CD40LG[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号（Catalog No.）
CSD00002
通用名INN
Ruplizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.Ruplizumab is an anti-CD40L monoclonal antibody.The binding of CD40 to its ligand,CD40L is a critical element in T cell activation.In systemic lupus erythematosus,CD40L is over-expressed on T cells, B cells and monocytes.
别名(Alternative names)
BG-9588,hu5c8
靶点;物种(Specificity target name;species)
CD40LG[Homo sapiens]
靶点背景信息(Target information)
Interleukin-17A (IL17A) is also known as cytotoxic T-lymphocyte-associated antigen 8 (CTLA8),which is a proinflammatory cytokine produced by activated T cells. IL17A can regulate the activities of NF-kappaB and mitogen-activated protein kinases. Also,IL17A can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO).Furthermore,IL17A has been found both in glycosylated and nonglycosylated forms. High levels of IL-17 are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
分子量(MV)
145448.00 Da
CAS
220651-94-5
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
